Meanwhile, CIN GC also frequently harbors amplifications of genes coding for RTKs, such as EGFR, FGFR2, HER2, and MET (Deng et al. 2012; Kiyose et al. 2012), which represent either validated or putative therapeutic targets, and several are being explored in ongoing clinical trials. The gene discussed is FGFR2; the disease is gastric cancer.